NCT04721002: Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)

• NCT04721002: Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM) (MEDICI)

NCT04721002: Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM) (MEDICI)

Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to assess t(11;14) and BCL2 expression in adult participants with newly diagnosed and relapsed/refractory (R/R) MM.

Sponsor

AbbVie

---

ClinicalTrials.gov Identifier: NCT04721002

Official Title: MEDICI - t(11;14) and BCL2 Expression in Patients With Multiple Myeloma: Prevalence, Stability Across Lines of Therapy and Concordance Across Sample Types

First Posted : January 22, 2021

Click here for details on ClinicalTrials.gov

---

Location

United States, Louisiana

United States, Texas

South America

Argentina

Brazil

Australia, Victoria

Canada, Alberta

Europe

Asia

Croatia

Czechia

France

Germany

Greece

Ireland

Israel

Italy

Netherlands

Norway

Poland

Romania

Saudi Arabia

Slovenia

Spain

Taiwan

Turkey